ID   PGRC1_HUMAN             Reviewed;         195 AA.
AC   O00264; B7Z1L3; Q9UGJ9;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   18-JUN-2025, entry version 213.
DE   RecName: Full=Membrane-associated progesterone receptor component 1;
DE            Short=mPR;
DE   AltName: Full=Dap1 {ECO:0000303|PubMed:28396637};
DE   AltName: Full=IZA {ECO:0000303|PubMed:28396637};
GN   Name=PGRMC1 {ECO:0000312|HGNC:HGNC:16090};
GN   Synonyms=HPR6.6 {ECO:0000303|PubMed:9705155}, PGRMC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=9705155; DOI=10.1515/bchm.1998.379.7.907;
RA   Gerdes D., Wehling M., Leube B., Falkenstein E.;
RT   "Cloning and tissue expression of two putative steroid membrane
RT   receptors.";
RL   Biol. Chem. 379:907-911(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-109 (ISOFORM 1).
RX   PubMed=11697142; DOI=10.3109/10425170109042047;
RA   Bernauer S., Wehling M., Gerdes D., Falkenstein E.;
RT   "The human membrane progesterone receptor gene: genomic structure and
RT   promoter analysis.";
RL   DNA Seq. 12:13-25(2001).
RN   [7]
RP   PROTEIN SEQUENCE OF 48-67; 81-88; 105-119; 124-132 AND 173-192,
RP   PHOSPHORYLATION AT SER-181, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-57, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Prostate cancer;
RX   PubMed=17487921; DOI=10.1002/elps.200600782;
RA   Giorgianni F., Zhao Y., Desiderio D.M., Beranova-Giorgianni S.;
RT   "Toward a global characterization of the phosphoproteome in prostate cancer
RT   cells: identification of phosphoproteins in the LNCaP cell line.";
RL   Electrophoresis 28:2027-2034(2007).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa cells
RT   and high confident phosphopeptide identification by cross-validation of
RT   MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-57, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using sequential
RT   IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-54 AND SER-57, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-57 AND SER-181, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-57, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by enrichment
RT   and fractionation of phosphopeptides with strong anion exchange
RT   chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-57, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-57, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-57 AND SER-181, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   CAUTION.
RX   PubMed=21730960; DOI=10.1038/ncomms1386;
RA   Xu J., Zeng C., Chu W., Pan F., Rothfuss J.M., Zhang F., Tu Z., Zhou D.,
RA   Zeng D., Vangveravong S., Johnston F., Spitzer D., Chang K.C.,
RA   Hotchkiss R.S., Hawkins W.G., Wheeler K.T., Mach R.H.;
RT   "Identification of the PGRMC1 protein complex as the putative sigma-2
RT   receptor binding site.";
RL   Nat. Commun. 2:380-380(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-57 AND SER-181, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [23]
RP   CAUTION.
RX   PubMed=22292588; DOI=10.1517/17425255.2012.658367;
RA   Ahmed I.S., Chamberlain C., Craven R.J.;
RT   "S2R(Pgrmc1): the cytochrome-related sigma-2 receptor that regulates lipid
RT   and drug metabolism and hormone signaling.";
RL   Expert Opin. Drug Metab. Toxicol. 8:361-370(2012).
RN   [24]
RP   MISCELLANEOUS, REVIEW, AND SUBUNIT.
RX   PubMed=23763432; DOI=10.1111/jne.12060;
RA   Petersen S.L., Intlekofer K.A., Moura-Conlon P.J., Brewer D.N.,
RA   Del Pino Sans J., Lopez J.A.;
RT   "Nonclassical progesterone signalling molecules in the nervous system.";
RL   J. Neuroendocrinol. 25:991-1001(2013).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-57 AND SER-181, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-54; SER-57; THR-74 AND
RP   SER-181, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   TISSUE SPECIFICITY.
RX   PubMed=23793472; DOI=10.1177/1933719113492208;
RA   Bunch K., Tinnemore D., Huff S., Hoffer Z.S., Burney R.O., Stallings J.D.;
RT   "Expression patterns of progesterone receptor membrane components 1 and 2
RT   in endometria from women with and without endometriosis.";
RL   Reprod. Sci. 21:190-197(2014).
RN   [28]
RP   FUNCTION.
RX   PubMed=25675345; DOI=10.1021/bi501177e;
RA   Kaluka D., Batabyal D., Chiang B.Y., Poulos T.L., Yeh S.R.;
RT   "Spectroscopic and mutagenesis studies of human PGRMC1.";
RL   Biochemistry 54:1638-1647(2015).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [30]
RP   FUNCTION, INTERACTION WITH FECH, AND HEME-BINDING.
RX   PubMed=27599036; DOI=10.1021/acs.biochem.6b00756;
RA   Piel R.B. III, Shiferaw M.T., Vashisht A.A., Marcero J.R., Praissman J.L.,
RA   Phillips J.D., Wohlschlegel J.A., Medlock A.E.;
RT   "A Novel Role for Progesterone Receptor Membrane Component 1 (PGRMC1): A
RT   Partner and Regulator of Ferrochelatase.";
RL   Biochemistry 55:5204-5217(2016).
RN   [31]
RP   REVIEW, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND MISCELLANEOUS.
RX   PubMed=28396637; DOI=10.3389/fphar.2017.00159;
RA   Ryu C.S., Klein K., Zanger U.M.;
RT   "Membrane associated progesterone receptors: promiscuous proteins with
RT   pleiotropic functions - focus on interactions with cytochromes P450.";
RL   Front. Pharmacol. 8:159-159(2017).
RN   [32]
RP   CAUTION.
RX   PubMed=28559337; DOI=10.1073/pnas.1705154114;
RA   Alon A., Schmidt H.R., Wood M.D., Sahn J.J., Martin S.F., Kruse A.C.;
RT   "Identification of the gene that codes for the sigma2 receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:7160-7165(2017).
RN   [33]
RP   CAUTION.
RX   PubMed=28007569; DOI=10.1016/j.phrs.2016.12.023;
RA   Pati M.L., Groza D., Riganti C., Kopecka J., Niso M., Berardi F., Hager S.,
RA   Heffeter P., Hirai M., Tsugawa H., Kabe Y., Suematsu M., Abate C.;
RT   "Sigma-2 receptor and progesterone receptor membrane component 1 (PGRMC1)
RT   are two different proteins: Proofs by fluorescent labeling and binding of
RT   sigma-2 receptor ligands to PGRMC1.";
RL   Pharmacol. Res. 117:67-74(2017).
RN   [34]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TMEM97 AND LDLR.
RX   PubMed=30443021; DOI=10.1038/s41598-018-35430-3;
RA   Riad A., Zeng C., Weng C.C., Winters H., Xu K., Makvandi M., Metz T.,
RA   Carlin S., Mach R.H.;
RT   "Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization
RT   of LDL by LDL Receptor through the Formation of a Ternary Complex.";
RL   Sci. Rep. 8:16845-16845(2018).
RN   [35]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND GLYCOSYLATION.
RX   PubMed=36213313; DOI=10.1007/s42485-022-00092-3;
RA   Ramarajan M.G., Saraswat M., Budhraja R., Garapati K., Raymond K.,
RA   Pandey A.;
RT   "Mass spectrometric analysis of chondroitin sulfate-linked peptides.";
RL   J. Proteins Proteom. 13:187-203(2022).
RN   [36]
RP   INTERACTION WITH TMEM97 AND TSPO.
RX   PubMed=37047353; DOI=10.3390/ijms24076381;
RA   Thejer B.M., Infantino V., Santarsiero A., Pappalardo I., Abatematteo F.S.,
RA   Teakel S., Van Oosterum A., Mach R.H., Denora N., Lee B.C., Resta N.,
RA   Bagnulo R., Niso M., Contino M., Montsch B., Heffeter P., Abate C.,
RA   Cahill M.A.;
RT   "Sigma-2 Receptor Ligand Binding Modulates Association between TSPO and
RT   TMEM97.";
RL   Int. J. Mol. Sci. 24:0-0(2023).
RN   [37]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND GLYCOSYLATION.
RX   PubMed=37453717; DOI=10.1016/j.mcpro.2023.100617;
RA   Noborn F., Nilsson J., Sihlbom C., Nikpour M., Kjellen L., Larson G.;
RT   "Mapping the Human Chondroitin Sulfate Glycoproteome Reveals an Unexpected
RT   Correlation Between Glycan Sulfation and Attachment Site Characteristics.";
RL   Mol. Cell. Proteomics 22:100617-100617(2023).
RN   [38] {ECO:0007744|PDB:4X8Y}
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 72-195 IN COMPLEX WITH HEME,
RP   INTERACTION WITH CYP1A1; CYP3A4 AND EGFR, SUBUNIT, HEME-BINDING, FUNCTION,
RP   AND MUTAGENESIS OF TYR-113.
RX   PubMed=26988023; DOI=10.1038/ncomms11030;
RA   Kabe Y., Nakane T., Koike I., Yamamoto T., Sugiura Y., Harada E.,
RA   Sugase K., Shimamura T., Ohmura M., Muraoka K., Yamamoto A., Uchida T.,
RA   Iwata S., Yamaguchi Y., Krayukhina E., Noda M., Handa H., Ishimori K.,
RA   Uchiyama S., Kobayashi T., Suematsu M.;
RT   "Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer
RT   proliferation and chemoresistance.";
RL   Nat. Commun. 7:11030-11030(2016).
CC   -!- FUNCTION: Component of a progesterone-binding protein complex
CC       (PubMed:28396637). Binds progesterone (PubMed:25675345). Has many
CC       reported cellular functions (heme homeostasis, interaction with CYPs).
CC       Required for the maintenance of uterine histoarchitecture and normal
CC       female reproductive lifespan (By similarity). Intracellular heme
CC       chaperone. Regulates heme synthesis via interactions with FECH and acts
CC       as a heme donor for at least some hemoproteins (PubMed:27599036). Forms
CC       a ternary complex with TMEM97 receptor and low density lipid
CC       receptor/LDLR, which increases LDLR-mediated LDL lipoprotein
CC       internalization (PubMed:30443021). {ECO:0000250|UniProtKB:O55022,
CC       ECO:0000269|PubMed:25675345, ECO:0000269|PubMed:27599036,
CC       ECO:0000269|PubMed:30443021, ECO:0000303|PubMed:28396637}.
CC   -!- SUBUNIT: Homodimer. Forms stable homodimer through hydrophobic heme-
CC       heme stacking interactions (PubMed:26988023, PubMed:28396637).
CC       Interacts with FECH; the interaction results in decreased FECH activity
CC       (PubMed:27599036). Interacts with EGFR, CYP1A1 and CYP3A4; the
CC       interactions require PGRMC1 homodimerization (PubMed:28396637).
CC       Interacts with TMEM97 and LDLR; the interaction increases LDL
CC       internalization (PubMed:30443021). Forms a complex with TMEM97 and
CC       TSPO; the interaction occurs in MIA PaCa-2 cells but not in MCF7 cells
CC       (PubMed:37047353). {ECO:0000269|PubMed:26988023,
CC       ECO:0000269|PubMed:27599036, ECO:0000269|PubMed:28396637,
CC       ECO:0000269|PubMed:30443021, ECO:0000269|PubMed:37047353,
CC       ECO:0000303|PubMed:28396637}.
CC   -!- INTERACTION:
CC       O00264; Q13323: BIK; NbExp=3; IntAct=EBI-1045534, EBI-700794;
CC       O00264; P49069: CAMLG; NbExp=3; IntAct=EBI-1045534, EBI-1748958;
CC       O00264; Q9H6E4: CCDC134; NbExp=3; IntAct=EBI-1045534, EBI-953766;
CC       O00264; O76071: CIAO1; NbExp=5; IntAct=EBI-1045534, EBI-725145;
CC       O00264; Q8NES8: DEFB124; NbExp=3; IntAct=EBI-1045534, EBI-12843376;
CC       O00264; Q15392: DHCR24; NbExp=2; IntAct=EBI-1045534, EBI-5457558;
CC       O00264; P34910-2: EVI2B; NbExp=3; IntAct=EBI-1045534, EBI-17640610;
CC       O00264; P22830: FECH; NbExp=4; IntAct=EBI-1045534, EBI-1390356;
CC       O00264; O43681: GET3; NbExp=3; IntAct=EBI-1045534, EBI-2515857;
CC       O00264; Q8NBJ4: GOLM1; NbExp=3; IntAct=EBI-1045534, EBI-712073;
CC       O00264; Q8N6L0: KASH5; NbExp=3; IntAct=EBI-1045534, EBI-749265;
CC       O00264; Q9UJ90: KCNE5; NbExp=3; IntAct=EBI-1045534, EBI-11981259;
CC       O00264; O15173: PGRMC2; NbExp=4; IntAct=EBI-1045534, EBI-1050125;
CC       O00264; P16435: POR; NbExp=6; IntAct=EBI-1045534, EBI-726554;
CC       O00264; Q96EQ0: SGTB; NbExp=3; IntAct=EBI-1045534, EBI-744081;
CC       O00264; Q9NQZ8: ZNF71; NbExp=5; IntAct=EBI-1045534, EBI-7138235;
CC       O00264; P00181: CYP2C2; Xeno; NbExp=6; IntAct=EBI-1045534, EBI-4320576;
CC   -!- SUBCELLULAR LOCATION: Microsome membrane
CC       {ECO:0000250|UniProtKB:Q95250}; Single-pass membrane protein
CC       {ECO:0000255}. Smooth endoplasmic reticulum membrane
CC       {ECO:0000303|PubMed:28396637}; Single-pass membrane protein
CC       {ECO:0000255}. Mitochondrion outer membrane
CC       {ECO:0000250|UniProtKB:O55022}; Single-pass membrane protein
CC       {ECO:0000305}; Extracellular side {ECO:0000250|UniProtKB:O55022}.
CC       Secreted {ECO:0000269|PubMed:36213313, ECO:0000269|PubMed:37453717}.
CC       Note=Localized at cell membrane, probably in lipid rafts, in serum-
CC       starved conditions. {ECO:0000269|PubMed:30443021}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O00264-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O00264-2; Sequence=VSP_054710;
CC   -!- TISSUE SPECIFICITY: Detected in urine (at protein level)
CC       (PubMed:36213313, PubMed:37453717). Expressed by endometrial glands and
CC       stroma (at protein level) (PubMed:23793472). Widely expressed, with
CC       highest expression in liver and kidney. {ECO:0000269|PubMed:23793472,
CC       ECO:0000269|PubMed:36213313}.
CC   -!- DOMAIN: The cytochrome b5 heme-binding domain lacks the conserved iron-
CC       binding His residues at positions 107 and 131. {ECO:0000250}.
CC   -!- PTM: O-glycosylated; contains chondroitin sulfate attached to Ser-54.
CC       Ser-54 is in the cytoplasmic domain but the glycosylated form was
CC       detected in urine, suggesting that the membrane-bound form is cleaved,
CC       allowing for production of a secreted form which is glycosylated.
CC       {ECO:0000269|PubMed:36213313, ECO:0000269|PubMed:37453717}.
CC   -!- MISCELLANEOUS: Non-classical progesterone receptors involved in
CC       extranuclear signaling are classified in 2 groups: the class II
CC       progestin and adipoQ receptor (PAQR) family (also called mPRs) (PAQR5,
CC       PAQR6, PAQR7, PAQR8 and PAQR9) and the b5-like heme/steroid-binding
CC       protein family (also called MAPRs) (PGRMC1, PGRMC2, NENF and CYB5D2).
CC       {ECO:0000303|PubMed:23763432, ECO:0000303|PubMed:28396637}.
CC   -!- SIMILARITY: Belongs to the cytochrome b5 family. MAPR subfamily.
CC       {ECO:0000305}.
CC   -!- CAUTION: Was initially identified as sigma-2 receptor, which is thought
CC       to play important role in regulating cell survival, morphology and
CC       differentiation (PubMed:21730960, PubMed:22292588, PubMed:28007569).
CC       However, it was later shown that it is not the case (PubMed:28007569).
CC       The sigma-2 receptor has been identified as TMEM97 (AC Q5BJF2)
CC       (PubMed:28559337). {ECO:0000269|PubMed:21730960,
CC       ECO:0000269|PubMed:22292588, ECO:0000269|PubMed:28007569,
CC       ECO:0000269|PubMed:28559337}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y12711; CAA73248.1; -; mRNA.
DR   EMBL; AK293618; BAH11549.1; -; mRNA.
DR   EMBL; AC004835; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471161; EAW89881.1; -; Genomic_DNA.
DR   EMBL; BC034238; AAH34238.1; -; mRNA.
DR   EMBL; AJ249131; CAB65109.1; -; Genomic_DNA.
DR   CCDS; CCDS14576.1; -. [O00264-1]
DR   CCDS; CCDS65313.1; -. [O00264-2]
DR   RefSeq; NP_001269550.1; NM_001282621.2. [O00264-2]
DR   RefSeq; NP_006658.1; NM_006667.5. [O00264-1]
DR   PDB; 4X8Y; X-ray; 1.95 A; A/B=72-195.
DR   PDBsum; 4X8Y; -.
DR   AlphaFoldDB; O00264; -.
DR   SMR; O00264; -.
DR   BioGRID; 116068; 401.
DR   CORUM; O00264; -.
DR   FunCoup; O00264; 2282.
DR   IntAct; O00264; 203.
DR   MINT; O00264; -.
DR   STRING; 9606.ENSP00000217971; -.
DR   ChEMBL; CHEMBL4105706; -.
DR   DrugBank; DB00514; Dextromethorphan.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB01104; Sertraline.
DR   DrugCentral; O00264; -.
DR   TCDB; 9.B.433.1.5; the progesterone receptor membrane-associated component 2 (pgrmc2) family.
DR   GlyGen; O00264; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O00264; -.
DR   PhosphoSitePlus; O00264; -.
DR   SwissPalm; O00264; -.
DR   BioMuta; PGRMC1; -.
DR   OGP; O00264; -.
DR   jPOST; O00264; -.
DR   MassIVE; O00264; -.
DR   PaxDb; 9606-ENSP00000217971; -.
DR   PeptideAtlas; O00264; -.
DR   ProteomicsDB; 47815; -. [O00264-1]
DR   ProteomicsDB; 6345; -.
DR   Pumba; O00264; -.
DR   TopDownProteomics; O00264-1; -. [O00264-1]
DR   Antibodypedia; 497; 208 antibodies from 36 providers.
DR   DNASU; 10857; -.
DR   Ensembl; ENST00000217971.8; ENSP00000217971.7; ENSG00000101856.10. [O00264-1]
DR   Ensembl; ENST00000535419.2; ENSP00000442821.1; ENSG00000101856.10. [O00264-2]
DR   GeneID; 10857; -.
DR   KEGG; hsa:10857; -.
DR   MANE-Select; ENST00000217971.8; ENSP00000217971.7; NM_006667.5; NP_006658.1.
DR   UCSC; uc011mts.4; human. [O00264-1]
DR   AGR; HGNC:16090; -.
DR   CTD; 10857; -.
DR   DisGeNET; 10857; -.
DR   GeneCards; PGRMC1; -.
DR   HGNC; HGNC:16090; PGRMC1.
DR   HPA; ENSG00000101856; Tissue enhanced (liver).
DR   MalaCards; PGRMC1; -.
DR   MIM; 300435; gene.
DR   OpenTargets; ENSG00000101856; -.
DR   Orphanet; 98994; Total early-onset cataract.
DR   VEuPathDB; HostDB:ENSG00000101856; -.
DR   eggNOG; KOG1110; Eukaryota.
DR   GeneTree; ENSGT00940000160619; -.
DR   HOGENOM; CLU_042860_5_0_1; -.
DR   InParanoid; O00264; -.
DR   OMA; ANEWETQ; -.
DR   OrthoDB; 547796at2759; -.
DR   PAN-GO; O00264; 2 GO annotations based on evolutionary models.
DR   PhylomeDB; O00264; -.
DR   PathwayCommons; O00264; -.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SignaLink; O00264; -.
DR   BioGRID-ORCS; 10857; 17 hits in 781 CRISPR screens.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   ChiTaRS; PGRMC1; human.
DR   GeneWiki; PGRMC1; -.
DR   GenomeRNAi; 10857; -.
DR   Pharos; O00264; Tchem.
DR   PRO; PR:O00264; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; O00264; protein.
DR   Bgee; ENSG00000101856; Expressed in seminal vesicle and 215 other cell types or tissues.
DR   ExpressionAtlas; O00264; baseline and differential.
DR   GO; GO:0044297; C:cell body; ISS:ARUK-UCL.
DR   GO; GO:0012505; C:endomembrane system; IBA:GO_Central.
DR   GO; GO:0005783; C:endoplasmic reticulum; IBA:GO_Central.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005741; C:mitochondrial outer membrane; ISS:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; ISS:ARUK-UCL.
DR   GO; GO:0043025; C:neuronal cell body; ISS:ARUK-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:ARUK-UCL.
DR   GO; GO:0030868; C:smooth endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0035579; C:specific granule membrane; TAS:Reactome.
DR   GO; GO:0045202; C:synapse; ISS:ARUK-UCL.
DR   GO; GO:0001540; F:amyloid-beta binding; TAS:ARUK-UCL.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0005496; F:steroid binding; TAS:ProtInc.
DR   GO; GO:0008306; P:associative learning; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0006783; P:heme biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0099563; P:modification of synaptic structure; IEA:Ensembl.
DR   GO; GO:1905809; P:negative regulation of synapse organization; IEA:Ensembl.
DR   GO; GO:0140077; P:positive regulation of lipoprotein transport; IMP:UniProtKB.
DR   GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IMP:ARUK-UCL.
DR   FunFam; 3.10.120.10:FF:000003; membrane-associated progesterone receptor component 1; 1.
DR   Gene3D; 3.10.120.10; Cytochrome b5-like heme/steroid binding domain; 1.
DR   InterPro; IPR001199; Cyt_B5-like_heme/steroid-bd.
DR   InterPro; IPR036400; Cyt_B5-like_heme/steroid_sf.
DR   InterPro; IPR050577; MAPR/NEUFC/NENF-like.
DR   PANTHER; PTHR10281:SF23; MEMBRANE-ASSOCIATED PROGESTERONE RECEPTOR COMPONENT 1; 1.
DR   PANTHER; PTHR10281; MEMBRANE-ASSOCIATED PROGESTERONE RECEPTOR COMPONENT-RELATED; 1.
DR   Pfam; PF00173; Cyt-b5; 1.
DR   SMART; SM01117; Cyt-b5; 1.
DR   SUPFAM; SSF55856; Cytochrome b5-like heme/steroid binding domain; 1.
DR   neXtProt; NX_O00264; -.
DR   PharmGKB; PA33248; -.
DR   TreeFam; TF314562; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Direct protein sequencing;
KW   Endoplasmic reticulum; Glycoprotein; Iron; Lipid-binding; Membrane;
KW   Metal-binding; Microsome; Mitochondrion; Mitochondrion outer membrane;
KW   Phosphoprotein; Proteoglycan; Proteomics identification; Receptor;
KW   Reference proteome; Secreted; Steroid-binding; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..195
FT                   /note="Membrane-associated progesterone receptor component
FT                   1"
FT                   /id="PRO_0000121739"
FT   TOPO_DOM        1..24
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        25..43
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        44..195
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          72..171
FT                   /note="Cytochrome b5 heme-binding"
FT   REGION          51..71
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          173..195
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         113
FT                   /ligand="heme"
FT                   /ligand_id="ChEBI:CHEBI:30413"
FT                   /ligand_part="Fe"
FT                   /ligand_part_id="ChEBI:CHEBI:18248"
FT                   /note="axial binding residue"
FT                   /evidence="ECO:0000269|PubMed:26988023,
FT                   ECO:0007744|PDB:4X8Y"
FT   MOD_RES         54
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         57
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18318008, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19367720,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         74
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         181
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|Ref.7, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         110..162
FT                   /note="EGPYGVFAGRDASRGLATFCLDKEALKDEYDDLSDLTAAQQETLSDWESQFT
FT                   F -> V (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054710"
FT   MUTAGEN         113
FT                   /note="Y->F: Abolishes interaction with CYP1A1 and CYP3A4."
FT                   /evidence="ECO:0000269|PubMed:26988023"
FT   HELIX           75..78
FT                   /evidence="ECO:0007829|PDB:4X8Y"
FT   STRAND          82..87
FT                   /evidence="ECO:0007829|PDB:4X8Y"
FT   STRAND          89..93
FT                   /evidence="ECO:0007829|PDB:4X8Y"
FT   STRAND          96..99
FT                   /evidence="ECO:0007829|PDB:4X8Y"
FT   HELIX           101..103
FT                   /evidence="ECO:0007829|PDB:4X8Y"
FT   HELIX           104..107
FT                   /evidence="ECO:0007829|PDB:4X8Y"
FT   HELIX           114..116
FT                   /evidence="ECO:0007829|PDB:4X8Y"
FT   HELIX           122..127
FT                   /evidence="ECO:0007829|PDB:4X8Y"
FT   HELIX           132..134
FT                   /evidence="ECO:0007829|PDB:4X8Y"
FT   HELIX           142..144
FT                   /evidence="ECO:0007829|PDB:4X8Y"
FT   HELIX           147..163
FT                   /evidence="ECO:0007829|PDB:4X8Y"
FT   STRAND          164..170
FT                   /evidence="ECO:0007829|PDB:4X8Y"
SQ   SEQUENCE   195 AA;  21671 MW;  CCD5E802E1C9E604 CRC64;
     MAAEDVVATG ADPSDLESGG LLHEIFTSPL NLLLLGLCIF LLYKIVRGDQ PAASGDSDDD
     EPPPLPRLKR RDFTPAELRR FDGVQDPRIL MAINGKVFDV TKGRKFYGPE GPYGVFAGRD
     ASRGLATFCL DKEALKDEYD DLSDLTAAQQ ETLSDWESQF TFKYHHVGKL LKEGEEPTVY
     SDEEEPKDES ARKND
//
